STAT+: Tango Therapeutics to go public in $353 million SPAC deal
Cambridge biotech Tango Therapeutics is going public through a $353 million deal with a special purpose acquisition company, the precision cancer medicine firm announced Wednesday.
The SPAC, called BCTG Acquisition Corp., is backed by Boxer Capital, one of the biotech’s investors.
Continue to STAT+ to read the full story…
Read Original Article: STAT+: Tango Therapeutics to go public in $353 million SPAC deal »
